AGIO — Agios Pharmaceuticals, Inc.

Is AGIO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

Agios Pharmaceuticals, Inc. (AGIO) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $35.12. The rating moved from Neutral to Overbought on August 13, 2026.

See all overbought Healthcare stocks →

AI analysis

Agios Pharmaceuticals, Inc. (AGIO) is primarily driven by the value of its clinical-stage assets and any near-term readouts or regulatory events. The current market backdrop is steady, which should allow the stock to trade on idiosyncratic, pipeline-specific news rather than macro shocks in the immediate term. Elevated biotech M&A multiples create an external pathway to value realization, while partnerships and prior commercialization experience add strategic optionality. Major downside drivers include clinical failure, the need to raise dilutive capital, payer/pricing headwinds, and competitive encroachment. Absence of fresh EDGAR analysis in the provided window increases uncertainty about the latest cash/runway position, so outcomes will depend heavily on upcoming clinical milestones and any capital-market activity.

Key factors

  • Pipeline value and clinical-readout optionality: future clinical data and regulatory milestones are the primary drivers of valuation.
  • Partnerships and prior commercialization experience provide strategic optionality for asset development or out-licensing.
  • Biotech M&A environment is elevated, increasing the likelihood of strategic interest or asset sale as a value realization path.
  • Macroeconomic and market backdrop is currently steady with selective growth interest, which supports orderly trading around clinical news.
  • Limited near-term macro headlines and sector rotation into defensive areas reduce immediate market-driven volatility for small-cap biotech.
  • Lack of updated EDGAR/filing commentary in the provided window increases uncertainty around current balance-sheet specifics.

Risks

  • Clinical and regulatory risk: negative trial results or delays would materially depress valuation.
  • Cash runway and financing risk: potential need for dilutive capital if cash burn outpaces milestones or partnerships.
  • Commercial and reimbursement risk: pricing pressure from payers and evolving reimbursement dynamics could limit revenue potential for approved assets.
  • Competitive risk: multiple programs and sponsors in oncology/rare disease can erode market share or reduce peak revenues.
  • Execution risk: manufacturing, enrollment or partner coordination challenges could slow development timelines.
  • Information gap risk: limited recent public filing/commentary in the provided dataset increases short-term forecasting uncertainty.

See today's live rating, score and targets

Members see the live hourly rating for AGIO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.